arrow
S

Sandra Ortiz-Cuaran

cancer research center of lyon
H指数:28
被引数:2,931

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Editorial Expression of Concern: Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer

编辑关注声明:同时靶向IGF-1R和ALK在ALK融合阳性肺癌中的合理性

2025-11-200
OAAI
Advances in Lung Cancer Basic and Translational Research in 2025 – Overview and Perspectives Focusing on NSCLC

2025年肺癌基础与转化研究进展——聚焦NSCLC的概述与展望

2025-06-030
PRE
LIBELULE: A Randomized Phase III Study to Evaluate the Clinical Relevance of Early Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer

LIBELULE研究:一项随机III期研究,旨在评估早期液体活检在可疑转移性肺癌患者中的临床相关性。

2024-12-012
OAAI
Selective translational activation of PBK (PDZ- binding kinase) reveals a molecular vulnerability of drug-tolerant persister cells to targeted therapies in EGFR-mutant lung adenocarcinoma
2024-03-220
PRE
Non-small cell lung cancer: Artificial intelligence enables the identification of survival signatures complementary to an Immunologically active gene expression signature involving previous therapies

非小细胞肺癌: 人工智能可以识别与先前治疗相关的免疫活性基因表达特征互补的生存特征

2023-10-010
OA
Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients
2022-10-0118
OAAI
Epithelial-to-mesenchymal transition promotes immune escape by inducing CD70 in non-small cell lung cancer
2022-07-0119
OAAI
Targeting netrin-3 in small cell lung cancer and neuroblastoma
2021-03-1517
OAAI
Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non-Small Cell Lung Cancer

循环肿瘤DNA基因组学揭示BRAF突变转移性非小细胞肺癌患者对BRAF靶向治疗耐药的潜在机制

2020-12-0129
OAAI